Synopsis
Synopsis
0
VMF
0
Canada
0
Australia
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2-(4-((r)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
2. (2-(4-((r)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic Acid
3. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-
4. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, Dihydrochloride
5. Cetirizine (r)-form Dihydrochloride
6. Levocetirizine
7. Levocetirizine Hydrochloride
8. Levocetrizine
9. Ucb-28556
10. Xusal
11. Xyzal
1. 130018-87-0
2. Xyzal
3. Xusal
4. (r)-cetirizine Dihydrochloride
5. Levocetirizine Hcl
6. Levocetirizine Dihydrochloride [usan]
7. Cetirizine (r)-form Dihydrochloride
8. Ucb-28556
9. Sod6a38aga
10. Ucb 28556
11. (2-(4-((r)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
12. (r)-2-(2-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic Acid Dihydrochloride
13. Acetic Acid, (2-(4-((r)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, Dihydrochloride
14. Nsc-758898
15. Levocetirizine Hydrochloride (jan)
16. (-)-cetirizine Dihydrochloride
17. 2-[2-[4-[(r)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid;dihydrochloride
18. 2-[2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic Acid Dihydrochloride
19. Levocetirizine (dihydrochloride)
20. Levocetirizine Hydrochloride [jan]
21. Levocetirizine 2hcl
22. Unii-sod6a38aga
23. Levocetirizine Dihcl
24. Mfcd07366507
25. Xyzal Allergy 24hr
26. Xyzal (tn)
27. Levocetirizinedihydrochloride
28. Schembl144375
29. Chembl1201190
30. Levocetirizine Hydrochloride,(s)
31. Dtxsid30926567
32. Bcp21544
33. Ac-549
34. Levocetirizine Dihydrochloride (usp)
35. S4849
36. Akos015994681
37. Ccg-269359
38. Cs-w011557
39. Hy-w010841
40. Ks-1177
41. Nsc 758898
42. [2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic Acid 2hcl
43. 2-[2-[4-[(r)-(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid Dihydrochloride
44. Levocetirizine Hydrochloride [mart.]
45. L0264
46. Levocetirizine Dihydrochloride [vandf]
47. Levocetirizine(r)-cetirizine (hydrochloride)
48. D08118
49. Levocetirizine Dihydrochloride [usp-rs]
50. Levocetirizine Dihydrochloride [who-dd]
51. Levocetirizine Dihydrochloride, >=98% (hplc)
52. Cetirizine (r)-form Dihydrochloride [mi]
53. 018l870
54. Levocetirizine Dihydrochloride [orange Book]
55. Levocetirizine Dihydrochloride [usp Monograph]
56. Q27289313
57. [2-[4-[(r)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic Acid Dihydrochloride
Molecular Weight | 461.8 g/mol |
---|---|
Molecular Formula | C21H27Cl3N2O3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 8 |
Exact Mass | 460.108726 g/mol |
Monoisotopic Mass | 460.108726 g/mol |
Topological Polar Surface Area | 53 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 443 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 4 | |
---|---|
Drug Name | Levocetirizine dihydrochloride |
Drug Label | Levocetirizine dihydrochloride, the active component of levocetirizine dihydrochloride tablets, is an orally active H1-receptor antagonist. The chemical name is R-(+)-2-[2-[4-[(4-chlorophenyl) phenyl methyl] piperazin-1-yl] ethoxy] acetic acid dihydr... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Synthon Pharms; Apotex; Hetero Labs Ltd Iii; Sciegen Pharms; Taro Pharm Inds; Sun Pharma Global; Glenmark Generics; Teva Pharms; Micro Labs Ltd India; Dr Reddys Labs; L Perrigo |
2 of 4 | |
---|---|
Drug Name | Xyzal |
PubMed Health | Levocetirizine (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | Levocetirizine dihydrochloride, the active component of XYZAL tablets and oral solution, is an orally active H1receptor antagonist. The chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl] ethoxy] acetic acid dihydrochloride.... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Ucb |
3 of 4 | |
---|---|
Drug Name | Levocetirizine dihydrochloride |
Drug Label | Levocetirizine dihydrochloride, the active component of levocetirizine dihydrochloride tablets, is an orally active H1-receptor antagonist. The chemical name is R-(+)-2-[2-[4-[(4-chlorophenyl) phenyl methyl] piperazin-1-yl] ethoxy] acetic acid dihydr... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Synthon Pharms; Apotex; Hetero Labs Ltd Iii; Sciegen Pharms; Taro Pharm Inds; Sun Pharma Global; Glenmark Generics; Teva Pharms; Micro Labs Ltd India; Dr Reddys Labs; L Perrigo |
4 of 4 | |
---|---|
Drug Name | Xyzal |
PubMed Health | Levocetirizine (By mouth) |
Drug Classes | Respiratory Agent |
Drug Label | Levocetirizine dihydrochloride, the active component of XYZAL tablets and oral solution, is an orally active H1receptor antagonist. The chemical name is (R)-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl] ethoxy] acetic acid dihydrochloride.... |
Active Ingredient | Levocetirizine dihydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | 2.5mg/5ml; 5mg |
Market Status | Prescription |
Company | Ucb |
Histamine H1 Antagonists, Non-Sedating
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
59
PharmaCompass offers a list of Levocetirizine Dihydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Levocetirizine Dihydrochloride manufacturer or Levocetirizine Dihydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Levocetirizine Dihydrochloride manufacturer or Levocetirizine Dihydrochloride supplier.
PharmaCompass also assists you with knowing the Levocetirizine Dihydrochloride API Price utilized in the formulation of products. Levocetirizine Dihydrochloride API Price is not always fixed or binding as the Levocetirizine Dihydrochloride Price is obtained through a variety of data sources. The Levocetirizine Dihydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Xyzall manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Xyzall, including repackagers and relabelers. The FDA regulates Xyzall manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Xyzall API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Xyzall manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Xyzall supplier is an individual or a company that provides Xyzall active pharmaceutical ingredient (API) or Xyzall finished formulations upon request. The Xyzall suppliers may include Xyzall API manufacturers, exporters, distributors and traders.
click here to find a list of Xyzall suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Xyzall DMF (Drug Master File) is a document detailing the whole manufacturing process of Xyzall active pharmaceutical ingredient (API) in detail. Different forms of Xyzall DMFs exist exist since differing nations have different regulations, such as Xyzall USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Xyzall DMF submitted to regulatory agencies in the US is known as a USDMF. Xyzall USDMF includes data on Xyzall's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Xyzall USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Xyzall suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Xyzall Drug Master File in Japan (Xyzall JDMF) empowers Xyzall API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Xyzall JDMF during the approval evaluation for pharmaceutical products. At the time of Xyzall JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Xyzall suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Xyzall Drug Master File in Korea (Xyzall KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Xyzall. The MFDS reviews the Xyzall KDMF as part of the drug registration process and uses the information provided in the Xyzall KDMF to evaluate the safety and efficacy of the drug.
After submitting a Xyzall KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Xyzall API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Xyzall suppliers with KDMF on PharmaCompass.
A Xyzall CEP of the European Pharmacopoeia monograph is often referred to as a Xyzall Certificate of Suitability (COS). The purpose of a Xyzall CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Xyzall EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Xyzall to their clients by showing that a Xyzall CEP has been issued for it. The manufacturer submits a Xyzall CEP (COS) as part of the market authorization procedure, and it takes on the role of a Xyzall CEP holder for the record. Additionally, the data presented in the Xyzall CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Xyzall DMF.
A Xyzall CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Xyzall CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Xyzall suppliers with CEP (COS) on PharmaCompass.
A Xyzall written confirmation (Xyzall WC) is an official document issued by a regulatory agency to a Xyzall manufacturer, verifying that the manufacturing facility of a Xyzall active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Xyzall APIs or Xyzall finished pharmaceutical products to another nation, regulatory agencies frequently require a Xyzall WC (written confirmation) as part of the regulatory process.
click here to find a list of Xyzall suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Xyzall as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Xyzall API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Xyzall as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Xyzall and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Xyzall NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Xyzall suppliers with NDC on PharmaCompass.
Xyzall Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Xyzall GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Xyzall GMP manufacturer or Xyzall GMP API supplier for your needs.
A Xyzall CoA (Certificate of Analysis) is a formal document that attests to Xyzall's compliance with Xyzall specifications and serves as a tool for batch-level quality control.
Xyzall CoA mostly includes findings from lab analyses of a specific batch. For each Xyzall CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Xyzall may be tested according to a variety of international standards, such as European Pharmacopoeia (Xyzall EP), Xyzall JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Xyzall USP).